TRIM21 and dermatomyositis: Recent studies have found that MDA5+ DM patients with co-existing anti-Ro52 antibodies have an increased frequency of RP-ILD and more aggressive phenotypes14,15, further highlighting that the breach of B cell tolerance likely contributes to the pathogenesis in MDA5+ DM.